Replies to post #46857 on OncoSec Medical Inc (ONCSQ)

[chickpea598]

I agree, this is positive. TNBC is a tough nut to crack and 20% response rates beats Keytruda monotherapy with 5%. Merck was the one who showed interest in TNBC combo therapy with Oncosec. PISCES can get an accelerated approval with a 20% BORR....and so can TNBC here in combo therapy. Merck will definitely be interested in Oncosec for these indications.